Meditope Nabs $3.6M to Turn MAbs into 'Legos'
Start-up Meditope Biosciences Inc. tucked $3.6 million under its belt in a Series A funded by angel investors to advance its monoclonal antibody (MAb) linker technology. The Los Angeles-based biotech is advancing cancer therapeutics discovered at City of Hope, a National Cancer Institute-designated Comprehensive Cancer Center in Duarte, Calif.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST